TTNP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TTNP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2025-04-12), Titan Pharmaceuticals's share price is $3.67. Titan Pharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.
The historical rank and industry rank for Titan Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:
During the past 13 years, the highest Price-to-Owner-Earnings of Titan Pharmaceuticals was 24.47. The lowest was 9.16. And the median was 16.83.
As of today (2025-04-12), Titan Pharmaceuticals's share price is $3.67. Titan Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-5.21. Therefore, Titan Pharmaceuticals's PE Ratio (TTM) for today is At Loss.
As of today (2025-04-12), Titan Pharmaceuticals's share price is $3.67. Titan Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was $-5.21. Therefore, Titan Pharmaceuticals's PE Ratio without NRI for today is At Loss.
During the past 13 years, Titan Pharmaceuticals's highest PE Ratio without NRI was 55.94. The lowest was 0.00. And the median was 23.51.
The historical data trend for Titan Pharmaceuticals's Price-to-Owner-Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Titan Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Price-to-Owner-Earnings | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
Titan Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Price-to-Owner-Earnings | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Titan Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Titan Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Titan Pharmaceuticals's Price-to-Owner-Earnings falls into.
In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Titan Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as
Price-to-Owner-Earnings | = | Share Price | / | Owner Earnings per Share (TTM) |
= | 3.67 | / | -8.06 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Titan Pharmaceuticals (NAS:TTNP) Price-to-Owner-Earnings Explanation
For how to get Owner Earnings per Share (TTM), please click.
Thank you for viewing the detailed overview of Titan Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.
Seow Gim Shen | 10 percent owner | NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000 |
Sire Group Ltd. | 10 percent owner | NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000 |
David Natan | director | 11190 BISCAYNE BLVD, MIAMI FL 33181 |
Matthew Charles Mcmurdo | director | 1047 SEWARD AVE., WESTFIELD NJ 07090 |
Peter Louis Chasey | director | 3295 N. FORT APACHE ROAD, STE. 110, LAS VEGAS NV 89129 |
Eric Howard Greenberg | director | 710 CARLYLE ST, WOODMERE NY 11598 |
Avraham Ben-tzvi | director | 44 ZAYT SHEMEN ST., FLAT 4, EFRAT L3 9045544 |
Katherine Beebe | director, officer: President and COO | 400 OYSTER POINT BLVD, SUITE 505, SOUTH SAN FRANCISCO CA 94080 |
Choon Hau Choong | 10 percent owner | NO. 23 LORONG TERUBONG RIA 2,, PAYA TERUBONG, GEORGE TOWN N8 11060 |
David E. Lazar | director, 10 percent owner, officer: Chief Executive Officer | VILLA 1, 14-43RD STREET, JUMEIRAH 2, DUBAI C0 00000 |
Activist Investing Llc | other: Member of 10% owner group | 1185 AVENUE OF THE AMERICAS, 3RD FLOOR., NEW YORK NY 10036 |
Joseph A Akers | director | 630 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10111 |
James R Mcnab | director | C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
Marc Rubin | director, officer: Executive Chairman | C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080 |
Dane Hallberg | officer: See Remarks | 400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By PurpleRose PurpleRose • 07-11-2022
By Marketwired • 08-19-2024
By PRNewswire PRNewswire • 07-15-2022
By PRNewswire • 09-04-2024
By Value_Insider Value_Insider • 12-12-2022
By PRNewswire • 09-04-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 06-25-2023
By PRNewswire PRNewswire • 07-05-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.